Mounjaro and Ozempic are both GLP-1 receptor agonists used for weight loss, but they may affect body composition differently. New research suggests that Mounjaro, which contains tirzepatide, causes greater loss of lean body mass compared to Ozempic, which contains semaglutide.
The distinction matters because lean body mass includes muscle, bone, and organs. Losing muscle alongside fat can undermine metabolism and physical function over time. When people lose weight rapidly without preserving muscle, they risk becoming weaker and struggling to maintain weight loss long term.
Mounjaro works through a dual mechanism, targeting both GLP-1 and GIP receptors. This dual action produces faster weight loss than semaglutide alone. However, speed comes with a tradeoff. When weight drops quickly, the body breaks down more muscle tissue for energy if caloric intake drops too sharply.
Researchers studying these medications have tracked body composition changes in people using each drug. Those taking Mounjaro experienced steeper declines in muscle mass relative to their total weight loss compared to those taking Ozempic. This pattern suggests that while both drugs work effectively for weight reduction, the rate and mechanism of weight loss differ.
The practical implication affects how people should approach these medications. Resistance training becomes even more important for Mounjaro users to combat muscle loss. Adequate protein intake during weight loss also helps preserve lean tissue. People considering either medication should discuss these differences with their doctors.
Neither drug is inherently "bad" for body composition. The choice depends on individual factors including health goals, exercise capacity, and existing muscle mass. Someone with significant muscle already may tolerate Mounjaro's effects differently than someone starting from a weaker baseline. Healthcare providers can help weigh whether the faster weight loss from Mounjaro justifies the greater lean mass loss